Alumis lupus trial misses endpoints as IFNGS-high subgroup offers a rescue path

The overall trial failed its core test. LUMUS did not meet its primary BICLA endpoint or key secondary endpoints in the full SLE population. 〔0〕 The placebo-adjusted BICLA differences were small and statistically inconclusive across all doses, while SRI-4 produced only one nominally significant dose response. That puts the study below the bar for an unselected Phase 3 program.

The company’s explanation is plausible but does not erase the miss. Forty percent of enrolled patients were IFNGS-low, a group Alumis says is less responsive to interferon-pathway treatment and more prone to placebo response. 〔1〕 That result shifts the development question from “does the drug work broadly in SLE?” to “can a biomarker-defined subgroup support a viable indication?”

The IFNGS-high subgroup provides a credible rescue signal, but it is not the headline result. In the prespecified IFNGS-high subgroup, BICLA response was 40.7%–52.6% on envudeucitinib versus 28.6% on placebo, and SRI-4 response was 57.8%–67.7% versus 33.1%. 〔2〕 The consistency across endpoints and doses supports further testing, but the subgroup analysis cannot fully substitute for the failed overall population result, particularly because the next trial would need narrower enrollment and a validated biomarker strategy.

Safety is a supporting positive, not a counterweight to the efficacy miss. The company reported generally good tolerability and no new safety signals. 〔3〕 Alumis plans FDA and EMA end-of-Phase-2 meetings to refine Phase 3 design, dose, enrollment criteria, and biomarker selection. 〔4〕 Net: the lupus opportunity is materially narrowed from a broad SLE thesis to a higher-risk, biomarker-selected development path.